Search Results for “ oncology” – Page 7 – media

Breaking news, Johnson & Johnson Medical Global Vice President resigns

Not long ago, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson & Johnson MedTech, announced his decision to resign. On the LinkedIn platform, Jones recalled fondly: “Looking back on the 35 glorious years spent at Johnson & Johnson, my heart is filled with deep nostalgia for the extraordinary times we have gone through together.” During his tenure in Johnson & Johnson’s medical device department, Jones was particularly committed to promoting the company’s innovation in oncology, orthopedics, cardiovascular and general surgery, and realizing the innovation of digital surgical connection solutions through advanced technologies such as surgical robots and machine learning platforms. As a senior technology executive, Jones has rich leadership experience. During his decades in office, he has led many major projects in Johnson & Johnson’s pharmaceutical and medical device departments, including the recent three-year, $200 million global digital transformation plan. According to LinkedIn information, Jones is ...
- Source: drugdu
- 44
- November 5, 2024
Domestic PD-L1 was approved in the UK for the first time

CStone Pharmaceuticals announced today (October 31) that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab combined with platinum-containing chemotherapy for patients without EGFR sensitive mutations, or without ALK, ROS1, First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with RET genomic tumor variants. This is the second marketing authorization application approval for sugalimab in overseas markets, following the approval by the European Commission. The approval was mainly based on the results of a multi-center, randomized, double-blind Phase III clinical study – GEMSTONE-302. Sugemalimab combined with chemotherapy can significantly extend the progression-free survival and overall survival of patients with newly treated metastatic NSCLC compared with placebo combined with chemotherapy. The research data has been published in The Lancet Oncology and Nature Cancer, and has been presented in oral and poster presentations at many international academic conferences. CStone Pharmaceuticals has reached a strategic cooperation with ...
- Source: drugdu
- 45
- November 4, 2024
Is the turning point of “Cosmic Pharmaceutical Factory” coming?

In 2022, Pfizer’s annual revenue exceeded $100 billion, making it the world’s largest pharmaceutical company in terms of revenue. However, as the COVID-19 pandemic quickly receded, revenue fell by 41% in 2023, and revenue ranking also dropped from first to fourth. Recently, the well-known radical investment institution Starboard Value invested $1 billion in Pfizer. What changes will this bring to this pharmaceutical giant? In 1849, Charles Pfizer and Charles Erhart founded Pfizer in New York, initially focusing on the production of chemical products. During World War II, Pfizer successfully mass-produced penicillin and launched oxytetracycline, officially entering the pharmaceutical industry. Since then, Pfizer has continued to expand through research and development and mergers and acquisitions, launched blockbuster drugs such as Norvasc and Viagra, and gradually became a leading global pharmaceutical company. Since the 21st century, Pfizer has topped the list of the top 50 pharmaceutical companies in the world (Pharm Exec ...
- Source: drugdu
- 64
- November 2, 2024
Medici Globalization Strategy Accelerates, Overseas Business Reaches New Heights

On the evening of October 30, Medici released its Q3 2024 report. In the third quarter, the company achieved operating revenue of 280 million yuan, a year-on-year decrease of 9.83%, and a net profit loss attributable to shareholders of approximately 58.44 million yuan. The company attributed this primarily to changes in the investment and financing environment for biomedicine during the reporting period, intensified industry competition, declining order prices, delays in executing some orders, and a decrease in gross profit margins. Domestic and international laboratory progress is promising, deepening the global strategic layout. As a pioneer of China’s Contract Research Organizations (CRO), Medici has maintained a forward-looking approach since its inception, adhering to a dual-market development strategy that encompasses both domestic and international markets. Its overseas operations span many regions, including the United States, Europe, Japan, and South Korea, and the company has established deep cooperative relationships with internationally renowned pharmaceutical ...
- Source: drugdu
- 54
- November 2, 2024
The first patient enrolled in the Phase III clinical trial of first-line treatment for biliary tract tumors using the head to head valumab regimen and the Ivo Western regimen

Recently, Kangfang Biotechnology (9926. HK) announced the completion of the first patient enrollment in a randomized, controlled, multicenter, registered Phase III clinical trial (HARMONI-GI-01/AK112-309) of its independently developed PD-1/VEGF bispecific antibody combination regimen with Ivexil and a comparison with Valiumab (PD-L1) combination regimen for first-line treatment of advanced biliary malignancies (BTC). Research on AK112-309 The HARMONI-GI-01/AK112-309 study was conducted by renowned domestic liver and gallbladder tumor experts, Professor Zhou Jian from Zhongshan Hospital affiliated with Fudan University and Professor Zheng Tongsen from Harbin Medical University Cancer Hospital, as co principal investigators. The endpoint of the study was overall survival (OS). The HARMONI-GI-01/AK112-309 study is the sixth registered phase III clinical trial conducted by Ecovaci, using PD-1/L1 monoclonal antibodies as control drugs. It reflects the company’s determination and confidence in iterating the current tumor immunotherapy landscape and establishing better global cancer standard treatments. It also demonstrates the ability of Kangfang Biotech ...
- Source: drugdu
- 47
- November 2, 2024
Huiyu Pharmaceuticals was the first company to pass the review for its “Detoxification Injection”

From October 14 to October 20, a total of 59 varieties passed/are deemed to have passed the consistency evaluation. During the same period, 88 varieties applied for consistency evaluation. Huiyu Pharmaceutical: Acetylcysteine Injection According to the official website of NMPA, Huiyu Pharmaceutical’s acetylcysteine injection was approved for marketing on October 16. The specifications approved this time are: 30ml: 6g, and the indications are detoxification of acute acetaminophen poisoning, used to prevent or alleviate liver damage caused by its overdose. Acetylcysteine is a precursor of reduced glutathione (GSH) and is an oxygen free radical scavenger in the body. The mechanism of its liver protection is still unclear, and may be related to maintaining or restoring glutathione levels. In addition, acetylcysteine may also play a liver protection role by improving hemodynamics and oxygen transport capacity and expanding microcirculation. As of now, Huiyu Pharmaceutical’s acetylcysteine injection is the first and only product of ...
- Source: drugdu
- 61
- October 31, 2024
GE Healthcare, this product is being produced for the first time in the United States

Recently, GE Healthcare is manufacturing the integrated Omni Legend PET/CT at its new production facility in Wisconsin. This marks the first time that the system has been produced domestically in the United States. 01. Innovative product Omni Legend PET/CT GE HealthCare launched its first PET/CT: Omni Legend on the fully digital Omni platform at the European Association for Nuclear Medicine (EANM) annual meeting in October 2022. The system achieved significant improvements in sensitivity, efficiency, radiation dose, and patient comfort. The system is equipped with a new digital BGO (dBGO) detector, aimed at improving examination efficiency, enhancing patient experience, and boosting diagnostic confidence. The system adopts a new category of digital BGO (dBGO) detector materials, with small crystal size and sensitivity more than twice that of existing digital scanners, which can achieve faster total scanning time and impressive small lesion detectability It aims to improve operational efficiency, enhance patient experience, and ...
- Source: drugdu
- 66
- October 30, 2024
Baiyu Pharmaceutical announces exclusive licensing agreement with Novartis for a small molecule anti-tumor drug

On October 17th, Baiyu Pharmaceutical announced an exclusive licensing agreement with Novartis for a small molecule anti-tumor drug. According to the agreement, Baiyu will receive a down payment of 70 million US dollars (approximately 499 million yuan), as well as various milestone payments and corresponding royalties for development, registration, and commercialization up to 1.1 billion US dollars (approximately 7.8 billion yuan). Novartis will obtain exclusive global development and commercialization rights for this small molecule innovative drug. Founded in 2005, Baiyu Pharmaceutical is headquartered in Chengdu, Sichuan. It is a global pharmaceutical enterprise with innovative drugs as its core, integrating research and development, production, sales, and traditional Chinese medicine cultivation into a full industry chain group. 10 pipelines under research, 5 tumor pipelines According to the announcement, the asset of this transaction is a small molecule innovative drug for the treatment of malignant tumors invented and discovered by the Baiyu Innovative ...
- Source: drugdu
- 67
- October 25, 2024
AI+drug target discovery | Insitro and Eli Lilly reach strategic agreement to jointly promote new therapies for metabolic diseases

Zhiyao Bang October 23, 2024 09:01 Shanghai On October 9, 2024, insitro, a new drug development company that supports machine learning, announced the signing of three strategic agreements with Eli Lilly, focusing on developing potential new drugs for the treatment of metabolic diseases, including metabolic dysfunction associated fatty liver (MASLD), based on the targets identified by insitro using the company’s AI based platform.Metabolic diseases, including MASLD, affect millions of people worldwide, but effective treatment options are still limited. The current treatment mainly treats the symptoms rather than the root cause. This collaboration aims to combine Insitro’s machine learning platform with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology to change existing models. According to the first two agreements, Insitro can choose to license Lilly’s proprietary, clinically advanced ternary N-acetylglucosamine (GalNAc) delivery technology, which will be combined with two different small interfering RNA (siRNA) molecules discovered and developed by ...
- Source: drugdu
- 74
- October 24, 2024
GE Healthcare launches its first CT production line in the country

Recently, GE Healthcare launched its first CT production line in France, marking a significant expansion of the company’s business at its Booker factory in the Yvelines department of France. It is reported that the new production line was announced in 2023 with the aim of improving the company’s agility, reducing carbon emissions, and better serving European customers. At present, the first scanner assembled in France, the Revolution Maxima CT, has been installed in the emergency department of Montargis Hospital Center in Loiret. The assembly of Revolution Maxima CT at Buc factory includes all functions and X-ray testing, system configuration, and direct delivery to European customers, which helps simplify the supply chain. It is understood that the new production line is part of GE Healthcare’s “In Europe for Europe” program, which is expected to reduce carbon emissions related to scanner transportation in Europe by 84%. This reduction is mainly due to ...
- Source: drugdu
- 77
- October 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.